Printer Friendly

THE LIPOSOME COMPANY DECLARES QUARTERLY DIVIDEND ON PREFERRED STOCK

 PRINCETON, N.J., Sept. 10 /PRNewswire/ -- The Liposome Company, Inc. (NASDAQ-NMS: LIPO, LIPOZ) announced today that its board of directors has declared a quarterly cash dividend on its 7-3/4 percent Series A Cumulative Convertible Exchangeable Preferred Stock at the prorated dividend rate of $.4844 per depositary share. The quarterly dividend is payable Oct. 15, 1993, to stockholders of record on Oct. 1, 1993.
 A leading company dedicated exclusively to the development of liposome and lipid-based pharmaceuticals, The Liposome Company develops proprietary parenteral pharmaceuticals for the treatment, prevention, and diagnosis of life-threatening diseases. The Liposome Company has four drugs currently in clinical trials. ABLC(TM) is in Phase II/III studies for the treatment of systemic fungal infections; Maitec(TM) is in Phase II trials in the United States and Phase III trials in Europe for the treatment of Mycobacterium avium-intracellulare (MAI), an infection that eventually strikes 30 to 50 percent of people with AIDS; TLC D-99 has completed Phase II for treatment of metastatic breast cancer; and TLC C-53 has completed Phase I trials in preparation for a Phase II study in Adult Respiratory Distress Syndrome.
 -0- 9/10/93
 /CONTACT: Edward G. Silverman, senior vice president - strategic operations of The Liposome Company, 609-452-7060/
 (LIPO)


CO: The Liposome Company, Inc. ST: New Jersey IN: MTC SU: DIV

GK-SH -- NY014 -- 0688 09/10/93 10:50 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 10, 1993
Words:227
Previous Article:PARAMOUNT COMMUNICATIONS REPORTS HIGHER FISCAL 1994 FIRST QUARTER RESULTS
Next Article:TOSCO CORPORATION DECLARES DIVIDEND
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters